In today's health care environment a product has to be effective and show real benefit. All the studies I have read on Pacira are rigged to show it works. That is not the question. The question my formulary committee asks is , Is it better than whats out there? The fact that liposomal bupivacaine works better than placebo is nice but the drug does not compete against placebo. Are there any studies that show how this drug works when compared against the On-Q or even ropivacaine? Is this drug available anywhere internationally? Who holds international marketing rights? I am interested in the drug but until I can research more or you can help me find answers to these and other questions (royalties to anyone?). I will stay on the side lines. Finding a good study that shows this drug is better than current treatment as opposed to nothing would probably get me off the side line.
Read the research by outside investors that project conservative sales of $350 U.S., That is why both issues of stock first at $6.50 and then $9.50 sold with overallotment allocation of 900k shares. I look at least 3-4 research reports from investment firms that estimate these maybe conservative numbers.